AUTHOR=Sachs-Guedj Noemie , Hart Roger , Requena Antonio , Vergara Vanessa , Polyzos Nikolaos P. 

TITLE=Real-world practices of hormone monitoring during ovarian stimulation in assisted reproductive technology: a global online survey

JOURNAL=Frontiers in Endocrinology

VOLUME=14

YEAR=2023

URL=https://www.frontiersin.org/journals/endocrinology/articles/10.3389/fendo.2023.1260783

DOI=10.3389/fendo.2023.1260783

ISSN=1664-2392

ABSTRACT=<sec><title>Objective</title><p>The aim of this study is to understand the global practice of routine hormonal monitoring (HM) during ovarian stimulation (OS) in the context of assisted reproductive technique (ART) treatment.</p></sec><sec><title>Methods</title><p>An open-access questionnaire was available to 3,845 members of <ext-link ext-link-type="uri" xlink:href="https://IVF-Worldwide.com" xmlns:xlink="http://www.w3.org/1999/xlink">IVF-Worldwide.com</ext-link> from September 8 to October 13, 2021. The survey comprised 25 multiple-choice questions on when and how ultrasound (US) and hormone tests were conducted during ovarian stimulation OS. For most questions, respondents were required to select a single option. Some questions allowed the selection of multiple options.</p></sec><sec><title>Results</title><p>In all, 528 (13.7%) members from 88 countries responded to the questionnaire. Most respondents (98.9%) reported using US to monitor OS cycles. HM was used by 79.5% of respondents during any of the cycle monitoring visits and was most commonly performed on the day of, or a day prior to final oocyte maturation. Overall, 87% of respondents claimed adjusting the dose of gonadotropin during OS, with 61.7% adjusting the dose based on hormonal levels. Oestradiol (E2) was the most frequently monitored hormone during all visits and was used by 74% of respondents for the prediction of ovarian hyperstimulation syndrome (OHSS). On or a day prior to ovulation triggering (OT), the number of respondents who measured progesterone increased from 34.3% in the second/third visit to 67.7%. Approximately one-third of respondents measured luteinizing hormone during all visits.</p></sec><sec><title>Conclusion</title><p>Globally, most ART specialists (~80%) use HM, along with US, for monitoring OS, especially for the prevention of OHSS.</p></sec>